Analyst Price Target is $28.17
▲ +235.72% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Mersana Therapeutics in the last 3 months. The average price target is $28.17, with a high forecast of $33.00 and a low forecast of $18.00. The average price target represents a 235.72% upside from the last price of $8.39.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Mersana Therapeutics. This Buy consensus rating has held steady for over two years.
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing antibody drug conjugates that offer clinical benefit for cancer patients with significant unmet need. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA.